• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.

作者信息

Patel Rachna, Czuprynska Julia, Roberts Lara N, Vadher Bipin, Rea Catherine, Patel Raj, Gee Emma, Saul Gabrielle, Coles Evelyn, Brown Alison, Byrne Rosalind, Speed Vicky, Patel Jignesh P, Arya Roopen

机构信息

Department of Haematological Medicine, Kings College Hospital, United Kingdom of Great Britain and Northern Ireland.

Department of Haematological Medicine, Kings College Hospital, United Kingdom of Great Britain and Northern Ireland.

出版信息

Thromb Res. 2021 Jan;197:192-194. doi: 10.1016/j.thromres.2020.11.004. Epub 2020 Nov 7.

DOI:10.1016/j.thromres.2020.11.004
PMID:33227656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7648504/
Abstract
摘要

相似文献

1
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.在2019冠状病毒病大流行期间将华法林患者转换为直接口服抗凝剂。
Thromb Res. 2021 Jan;197:192-194. doi: 10.1016/j.thromres.2020.11.004. Epub 2020 Nov 7.
2
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.心脏病患者页面。心房颤动患者服用非维生素K拮抗剂口服抗凝剂的指南。
Circulation. 2015 Apr 21;131(16):e412-5. doi: 10.1161/CIRCULATIONAHA.114.012808.
3
Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?口服抗凝剂的长期治疗能否改善2019冠状病毒病（COVID-19）中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的临床病程？
Semin Thromb Hemost. 2021 Jun;47(4):338-340. doi: 10.1055/s-0040-1715091. Epub 2020 Sep 3.
4
Evaluation of Bleeding Rate and Time in Therapeutic Range in Patients Using Warfarin Before and During the COVID-19 Pandemic-Warfarin Treatment in COVID-19.评估 COVID-19 大流行期间和之前使用华法林的患者的出血率和治疗范围内的时间-COVID-19 中的华法林治疗。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211021495. doi: 10.1177/10760296211021495.
5
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].[新型口服抗凝药用于静脉血栓栓塞症。关于转换、监测、暂停用药的全科医学信息]
MMW Fortschr Med. 2015 Jan 19;157(1):24. doi: 10.1007/s15006-015-2575-7.
6
Anticoagulation and Renal Insufficiency.
Ther Umsch. 2016;73(10):567-572. doi: 10.1024/0040-5930/a000836.
7
Another novel oral anticoagulant matches warfarin.
JAMA. 2014 Jan 15;311(3):233-4. doi: 10.1001/jama.2013.284833.
8
[Edoxaban is safer than vitamin K antagonists].
MMW Fortschr Med. 2013 Sep 26;155(16):20. doi: 10.1007/s15006-013-2151-y.
9
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.新型口服抗凝剂对房颤患者胃肠道出血的影响：一项干预性试验的荟萃分析。
Dig Liver Dis. 2015 May;47(5):429-31. doi: 10.1016/j.dld.2015.01.159. Epub 2015 Feb 7.
10
Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19): Part II.2019冠状病毒病（COVID-19）中的止血维持与血栓形成预防：第二部分。
Semin Thromb Hemost. 2021 Jun;47(4):333-337. doi: 10.1055/s-0041-1728775. Epub 2021 Jun 1.

引用本文的文献

1
Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis.瑞典新冠疫情期间抗凝剂的启用：一项中断时间序列分析
Basic Clin Pharmacol Toxicol. 2025 Feb;136(2):e14119. doi: 10.1111/bcpt.14119.
2
Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation.2019年冠状病毒病大流行对接受口服抗凝剂治疗非瓣膜性心房颤动患者的影响。
Int J Cardiol Heart Vasc. 2024 Feb 10;51:101358. doi: 10.1016/j.ijcha.2024.101358. eCollection 2024 Apr.
3
A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study.
关于2019冠状病毒病大流行期间抗凝管理的德尔菲共识：摩纳哥研究
Cardiovasc Diagn Ther. 2023 Oct 31;13(5):777-791. doi: 10.21037/cdt-23-76. Epub 2023 Oct 25.
4
Impact of pharmacist intervention on anticoagulation management and risk for potential COVID-19 exposure during the COVID-19 pandemic.在 COVID-19 大流行期间，药师干预对抗凝管理和潜在 COVID-19 暴露风险的影响。
Thromb Res. 2022 Sep;217:52-56. doi: 10.1016/j.thromres.2022.07.004. Epub 2022 Jul 16.
5
Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.吸入型依度沙班干粉吸入剂制剂：研发、表征及其对 COVID-19 感染相关凝血障碍的影响。
Int J Pharm. 2021 Oct 25;608:121122. doi: 10.1016/j.ijpharm.2021.121122. Epub 2021 Sep 21.
6
Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil.新冠疫情期间的华法林抗凝治疗：巴西茹安维尔地区血液学门诊中心的电话管理模式
Thromb Res. 2021 Sep;205:81-83. doi: 10.1016/j.thromres.2021.07.006. Epub 2021 Jul 9.
7
Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?新冠疫情时代非瓣膜性心房颤动的抗凝治疗：是时候重新审视我们的治疗策略了吗？
Eur J Prev Cardiol. 2022 Nov 8;29(15):2069-2071. doi: 10.1093/eurjpc/zwab021.